Martinho Inês, Braz Márcia, Duarte João, Brás Ana, Oliveira Vanessa, Gomes Newton C M, Pereira Carla, Almeida Adelaide
Department of Biology and CESAM, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.
Microorganisms. 2024 Aug 29;12(9):1795. doi: 10.3390/microorganisms12091795.
is a common cause of hospital-acquired infections and exhibits a strong resistance to antibiotics. An alternative treatment option for bacterial infections is the use of bacteriophages (or phages). In this study, two distinct phages, VB_PaD_phPA-G (phPA-G) and VB_PaN_phPA-Intesti (phPA-Intesti), were used as single suspensions or in a phage cocktail to inactivate the planktonic cells and biofilms of . Preliminary experiments in culture medium showed that phage phPA-Intesti (reductions of 4.5-4.9 log CFU/mL) outperformed phPA-G (reductions of 0.6-2.6 log CFU/mL) and the phage cocktail (reduction of 4.2 log CFU/mL). Phage phPA-Intesti caused a maximum reduction of 5.5 log CFU/cm in the biofilm in urine after 4 h of incubation. The combination of phage phPA-Intesti and ciprofloxacin did not improve the efficacy of bacterial inactivation nor reduce the development of resistant mutants. However, the development of resistant bacteria was lower in the combined treatment with the phage and the antibiotic compared to treatment with the antibiotic alone. This phage lacks known toxins, virulence, antibiotic resistance, and integrase genes. Overall, the results suggest that the use of phage phPA-Intesti could be a potential approach to control urinary tract infections (UTIs), namely those caused by biofilm-producing and multidrug-resistant strains of .
是医院获得性感染的常见原因，并且对抗生素表现出很强的抗性。细菌感染的一种替代治疗选择是使用噬菌体（或简称噬菌体）。在本研究中，两种不同的噬菌体，VB_PaD_phPA - G（phPA - G）和VB_PaN_phPA - Intesti（phPA - Intesti），被用作单一悬浮液或制成噬菌体鸡尾酒来灭活浮游细胞和的生物膜。在培养基中的初步实验表明，噬菌体phPA - Intesti（降低4.5 - 4.9 log CFU/mL）比phPA - G（降低0.6 - 2.6 log CFU/mL）和噬菌体鸡尾酒（降低4.2 log CFU/mL）表现更好。噬菌体phPA - Intesti在孵育4小时后使尿液中的生物膜最大减少5.5 log CFU/cm。噬菌体phPA - Intesti和环丙沙星的组合既没有提高细菌灭活的效果，也没有减少抗性突变体的产生。然而，与单独使用抗生素治疗相比，噬菌体和抗生素联合治疗中耐药菌的产生较少。这种噬菌体缺乏已知的毒素、毒力、抗生素抗性和整合酶基因。总体而言，结果表明使用噬菌体phPA - Intesti可能是控制尿路感染（UTIs）的一种潜在方法，即由产生生物膜的多重耐药菌株引起的感染。
